Literature DB >> 31994839

The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma.

Shahar Frenkel1,2, Jacob Pe'er1, Ron Kaufman1, Bella Maly3, Zohar Habot-Wilner4.   

Abstract

PURPOSE: To evaluate the efficacy of the different diagnostic tests for vitreoretinal lymphoma (VRL).
METHODS: A cohort of 150 patients with a presumed diagnosis of VRL. Vitrectomy samples were analysed for cytology, monoclonality [polymerase chain reaction (PCR)] and cytokine levels, and anterior chamber taps were analysed for cytokine levels. Vitreoretinal lymphoma (VRL) was diagnosed after confirming the clinical suspicion with vitreal or brain cytology.
RESULTS: Vitreoretinal lymphoma (VRL) was diagnosed in 78 patients. Vitreal cytology was positive for 53/132 patients (40.2%), 36/53 had positive cytology from both the eye and the brain. Additional 25 patients had positive brain cytology. Vitreal PCR for monoclonality was positive for 32/91 patients (35.2%). Vitreal cytokine levels of interleukin (IL)-10/IL-6 were >1 for 47/110 patients (43.1%). For cytology, PCR and cytokine analysis, the respective sensitivity was 73.6%, 46.0% and 81.4%, and the accuracy of the tests was 85.6%, 60.4% and 80.9%, respectively. All three tests were available for 79 patients. In this subset, for cytology, PCR and cytokine analysis the respective sensitivity was 79.5%, 41.0% and 82.1%, respectively, and the accuracy of the tests was 89.9%, 60.8% and 81.0%, respectively.
CONCLUSION: Cytokines analysis has an important role in the diagnosis of VRL. We suggest analysing cytokines levels in all cases suspected of VRL along with cytology and PCR analysis.
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IL-10; PCR; cytology; diagnosis; vitreoretinal lymphoma

Mesh:

Substances:

Year:  2020        PMID: 31994839     DOI: 10.1111/aos.14347

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  6 in total

1.  Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.

Authors:  Rae-Young Kim; Jae Hyun Park; Mirinae Kim; Young-Geun Park; Seok-Goo Cho; Young-Hoon Park
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

2.  Logistic regression models of cytokines in differentiating vitreoretinal lymphoma from uveitis.

Authors:  Sha Tian; Kun Chen; Jianjiang Xiao; Xian Zhou; Huimin Shi; Yi Li; Hehe Huang; Yanchun Ma; Bobin Chen; Qingping Wang; Ming Guan
Journal:  J Clin Lab Anal       Date:  2022-09-13       Impact factor: 3.124

3.  Comparisons of Vitreal Angiogenic, Inflammatory, Profibrotic Cytokines, and Chemokines Profile between Patients with Epiretinal Membrane and Macular Hole.

Authors:  Lu Chen; Weiwei Zhang; Ping Xie; Jiangdong Ji; Huiming Qian; Songtao Yuan; Qinghuai Liu; Zizhong Hu
Journal:  J Ophthalmol       Date:  2021-07-13       Impact factor: 1.909

4.  Tear cytokine profiles in patients with extranodal marginal zone B-cell lymphoma of the ocular adnexa.

Authors:  Wei Xiao; Jingqiao Chen; Huijing Ye; Xiaoyun Chen; Yuxiang Mao; Xian Ji; Shenglan Yang; Huasheng Yang
Journal:  Eye (Lond)       Date:  2021-06-28       Impact factor: 4.456

5.  High-Throughput MicroRNA Profiling of Vitreoretinal Lymphoma: Vitreous and Serum MicroRNA Profiles Distinct from Uveitis.

Authors:  Teruumi Minezaki; Yoshihiko Usui; Masaki Asakage; Masakatsu Takanashi; Hiroyuki Shimizu; Naoya Nezu; Akitomo Narimatsu; Kinya Tsubota; Kazuhiko Umazume; Naoyuki Yamakawa; Masahiko Kuroda; Hiroshi Goto
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

6.  IL-10, IL-13, Eotaxin and IL-10/IL-6 ratio distinguish breast implant-associated anaplastic large-cell lymphoma from all types of benign late seromas.

Authors:  Rita Mancini; Marshall E Kadin; Arianna Di Napoli; Daniele Greco; Giorgia Scafetta; Francesca Ascenzi; Alessandro Gulino; Luigi Aurisicchio; Fabio Santanelli Di Pompeo; Adriana Bonifacino; Enrico Giarnieri; John Morgan
Journal:  Cancer Immunol Immunother       Date:  2020-11-04       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.